Fda Reauthorization Act of 2017by Representative Tony Cárdenas
Posted on 2017-07-12
CARDENAS. Mr. Speaker, I rise today to speak in support of H.R.
2430, the FDA Reauthorization Act.
I also would like to thank the chairman and ranking member of the Energy and Commerce Committee for working so hard to get this important bill on the floor here today.
This reauthorization bill provides the FDA with the resources to complete an important and difficult job: ensuring timely and efficient drug review processes while maintaining rigorous scientific and safety standards to maintain the safety, efficacy, and security of drugs, biological products, medical devices, and therapies that Americans have access to today and tomorrow.
I am lucky to have been born and raised in this great country where we have access to the latest innovation in the life sciences sector. I wish my parents had been raised right here in this great, wonderful country so they may still be here today, so that they could enjoy time with their grandchildren if I have been so blessed to do so myself.
The FDA is seen as the gold standard around the world, and this bill keeps us right there, right at the top.
I am encouraged to see my colleagues working together to ensure that the FDA is able to continue to fulfill this responsibility, and I look forward to continue working to have this reauthorization passed out of Congress.